ARTICLE | Company News
Depomed plummets on reduced sales guidance
August 8, 2017 11:35 PM UTC
Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its value on Tuesday, falling $3.08 (33%) to $6.14.
Management said increased regulatory and managed care pressure on the short- and long-acting opioid markets has dented the company's revenue expectations...
BCIQ Company Profiles